RxDoctor Payments Data

Shanna Rebholz, APRN

Family · Cincinnati, OHNPI 1700473329

Payments from drug & device makers

$3,831in general payments, 2019–2025

Across 184 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$850
  • Pfizer$318
  • Novartis$256
  • UCB, Inc.$255
  • Biogen$219
  • Axsome Therapeutics, Inc.$189
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,831 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$78,093
Medicare patients
51
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate16$124,476
TecfideraDimethyl Fumarate11$100,955
Dalfampridine ErDalfampridine12$4,141
Levetiracetam49$3,349
Oxcarbazepine12$2,050
Gabapentin84$1,148
Pregabalin21$935
Baclofen41$779
Carbidopa-LevodopaCarbidopa/Levodopa26$657
AmantadineAmantadine Hcl12$484
Duloxetine Hcl23$474
Divalproex Sodium ErDivalproex Sodium17$434
Methocarbamol32$430
Ropinirole Hcl24$371
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Tecfidera$219$225,43027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →